Last reviewed · How we verify
CV0601 mRNA COVID-19 Vaccine — Competitive Intelligence Brief
phase 2
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
CV0601 mRNA COVID-19 Vaccine (CV0601 mRNA COVID-19 Vaccine) — GlaxoSmithKline. CV0601 mRNA COVID-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CV0601 mRNA COVID-19 Vaccine TARGET | CV0601 mRNA COVID-19 Vaccine | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CV0601 mRNA COVID-19 Vaccine CI watch — RSS
- CV0601 mRNA COVID-19 Vaccine CI watch — Atom
- CV0601 mRNA COVID-19 Vaccine CI watch — JSON
- CV0601 mRNA COVID-19 Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). CV0601 mRNA COVID-19 Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/cv0601-mrna-covid-19-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab